Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment

Am J Hematol. 2003 Jan;72(1):43-52. doi: 10.1002/ajh.10263.

Abstract

The association between malignancy and clinical thrombosis has been recognized for nearly 140 years. The purpose of this review is to examine our current understanding of thrombosis as a complication of cancer and cancer therapy. The review includes a discussion of the epidemiology, pathophysiology, diagnosis and treatment.

Publication types

  • Review

MeSH terms

  • Algorithms
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Biomarkers
  • Catheterization, Central Venous / adverse effects
  • Cysteine Endopeptidases / metabolism
  • Diagnostic Imaging
  • Disseminated Intravascular Coagulation
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Incidence
  • Male
  • Neoplasm Proteins / metabolism
  • Neoplasms / blood
  • Neoplasms / complications*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Postoperative Complications / etiology
  • Thromboembolism / diagnosis
  • Thromboembolism / drug therapy
  • Thromboembolism / epidemiology
  • Thromboembolism / etiology*
  • Thromboembolism / prevention & control
  • Thrombophilia / diagnosis
  • Thrombophilia / epidemiology
  • Thrombophilia / etiology*
  • Venous Thrombosis / epidemiology
  • Venous Thrombosis / etiology

Substances

  • Anticoagulants
  • Biomarkers
  • Fibrinolytic Agents
  • Neoplasm Proteins
  • Platelet Aggregation Inhibitors
  • Cysteine Endopeptidases
  • cancer procoagulant